POLBF (Poolbeg Pharma) Forward Dividend Yield %: 0.00% (As of Jun. 24, 2026)


What is Poolbeg Pharma Forward Dividend Yield %?

Poolbeg Pharma POLBF -20.36% Forward Dividend Yield % is 0.00% as of Jun. 24, 2026. The stock has 1 warning sign investors should review. Among 147 Biotechnology companies, Poolbeg Pharma ranks worse than 680271.43% on this metric.

As of today (2026-06-24), the Forward Annual Dividend Yield of Poolbeg Pharma is 0.00%.

As of today (2026-06-24), the Trailing Annual Dividend Yield of Poolbeg Pharma is 0.00%.

POLBF's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.51
* Ranked among companies with meaningful Forward Dividend Yield % only.

Poolbeg Pharma's Dividends per Share for the six months ended in Dec. 2025 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Poolbeg Pharma  (OTCPK:POLBF) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Poolbeg Pharma Forward Dividend Yield % Related Terms

POLBF vs VRTX, REGN, ALNY: Forward Dividend Yield % Comparison

For the Biotechnology subindustry, Poolbeg Pharma's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poolbeg Pharma Forward Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poolbeg Pharma's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Poolbeg Pharma's Forward Dividend Yield % falls into.


Poolbeg Pharma Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Poolbeg Pharma (POLBF) has a Forward Dividend Yield % of 0.00% as of Jun. 24, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Poolbeg Pharma and its competitors. According to the industry distribution chart, Poolbeg Pharma ranks #999999 out of 147 companies in the Biotechnology industry.
Is Poolbeg Pharma's Forward Dividend Yield % too high?
Poolbeg Pharma's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Poolbeg Pharma ranks #999999 out of 147 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Poolbeg Pharma's Forward Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Poolbeg Pharma ranks #999999 out of 147 companies for Forward Dividend Yield %. This places Poolbeg Pharma in the lower half of its industry. The industry median Forward Dividend Yield % is 1.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.51, based on 147 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Poolbeg Pharma and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Poolbeg Pharma's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current Forward Dividend Yield % is 0.00% as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poolbeg Pharma Business Description

Other Exchanges POLB:UK7JN:Germany
Address 20 St. Andrew Street, The Clubhouse Holborn, London, GBR, EC4A 3AG
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.